Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium-99m ethambutol
- Development stage
- Unknown
- Lead developer
- National Research and Innovation Agency
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
Technetium-99m ethambutol (99mTc-ethambutol, 99mTc-EMB) is a diagnostic radiopharmaceutical developed for the non-invasive detection and localization of both pulmonary and extrapulmonary tuberculosis (TB). It is prepared by labeling the first-line antitubercular drug ethambutol with the gamma-emitting radionuclide technetium-99m. The radiotracer is selectively taken up by living *Mycobacterium tuberculosis* bacteria, where ethambutol binds to its biological target, arabinosyltransferase, which is involved in cell wall synthesis. This specific bacterial targeting allows for the differentiation of active tuberculosis infection from non-specific inflammation or malignancy. Developed in collaboration between the National Research and Innovation Agency of Indonesia (BRIN, formerly BATAN) and PT Kimia Farma Tbk, the diagnostic kit is marketed in Indonesia under the brand name TB-Scan and has received a distribution permit from the Indonesian Food and Drug Authority (BPOM).
- Brand names
- TB-Scan
- Other names
- 99mTc-EMB99mTc-ethambutoltechnetium (99mTc) ethambutoltechnetium Tc 99m ethambutol
02
Targets
AftA (Arabinosyltransferase AftA)
Beyond the preview
Go deeper on technetium-99m ethambutol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium-99m ethambutol.